PureTech Health PLC PRTC Notes IP For Health Assessments from Speech
September 20 2017 - 2:01AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
20 September 2017
20 September 2017
PureTech Health plc
PureTech Health Notes US Patent Issuance Broadly Covering
Methods of Assessing Mental and Physical Condition from Human
Speech
PureTech Health plc ("PureTech Health" or the "Company", LSE:
PRTC), an advanced, clinical-stage biopharmaceutical company, is
pleased to note that the United States Patent and Trademark Office
(USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal
biomarkers programme. The patent broadly covers methods of
assessing a mental or physical condition of a subject, using
phonetic structures, or phones, extracted from speech audio
waveforms. The issued patent is exclusively licensed under an
agreement with the Massachusetts Institute of Technology (MIT) and
provides coverage through at least 2032.
"This newly issued patent represents, to the best of our
knowledge, the only coverage for novel vocal biomarkers that have
been demonstrated to enhance vocal analysis performance for
assessment of a broad range of diseases," said Jim Harper, PhD,
PureTech Health Vocal Biomarker Programme Lead. "Issuance of this
patent strengthens our leading intellectual property portfolio in
the emerging field of acoustic voice analysis for health, and it
provides validation of our novel vocal biomarkers technology for
the assessment of mental and physical conditions."
The patented technology, created by a team at MIT Lincoln
Laboratory led by Thomas Quatieri, PhD, enables analysis of subtle
- yet quantifiable - changes in the voice to improve automated
measures of important aspects of an individual's health. Pilot
studies using the exclusively licensed technology have also
demonstrated the potential to detect and objectively measure
symptoms in a range of important conditions including depression,
mild traumatic brain injury (mTBI), concussion, cognitive
impairment and Parkinson's Disease. The vocal biomarkers programme
(Sonde) has been integrating and extending this technology for
analysis of an individual's voice on commonly-owned devices.
Testing of the Sonde technology in over a thousand subjects has
demonstrated the potential to effectively screen and monitor for
disease using only a few seconds of voice. The Sonde technology is
being developed to enable disease-associated features of speech to
be measured without capturing the contents of speech, therefore
protecting privacy.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced,
clinical-stage biopharmaceutical company developing novel medicines
targeting serious diseases that result from dysfunctions in the
nervous, immune, and gastrointestinal systems (brain-immune-gut or
the "BIG" axis), which together represent the adaptive human
systems. PureTech Health is at the forefront of understanding and
addressing the biological processes and crosstalk associated with
the BIG axis. By harnessing this emerging field of human biology,
the Company is pioneering new categories of medicine with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies that includes two pivotal or registration studies
expected to read out in 2017, multiple human proof-of-concept
studies and a number of early clinical and pre-clinical programmes.
PureTech's rich research and development pipeline has been advanced
in collaboration with some of the world's leading scientific
experts, who along with PureTech's team of biopharma pioneers,
entrepreneurs and seasoned Board, identify, invent, and clinically
de-risk new medicines. With this experienced team pursuing cutting
edge science, PureTech Health is building the biopharma company of
the future focused on improving and extending the lives of people
with serious disease. For more information, visit
www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech Health FTI Consulting
Allison Mead Talbot Ben Atwell, Rob
+1 617 651 3156 Winder
amt@puretechhealth.com +44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGMLZLVGNZZ
(END) Dow Jones Newswires
September 20, 2017 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2023 to Apr 2024